Amidoximes and their masked derivatives as prodrugs of amidines – arginine mimetics

Authors

  • O. V. Ovdiichuk Laboratoire de Chimie Physique Macromolecular, ENSIC, Universite de Lorraine, France
  • O. V. Hordiyenko Taras Shevchenko National University of Kyiv, Ukraine

DOI:

https://doi.org/10.24959/ophcj.16.878

Keywords:

amidoximes, prodrugs, synthesis, amidines, double prodrugs, bioactivation, bioavailability

Abstract

The literature data concerning the use of amidoximes as prodrugs of amidines – arginine mimics – have been systematized. The advantages of the use of amidoximes as prodrugs that have become a tool for improving physicochemical, biopharmaceutical or pharmacokinetic properties of pharmacologically active agents has been highlighted. The mechanism of their in vivo activation by the mARC-containing N-reductive enzyme system to release the active parent drug of amidoximes has been described. The data on application of the “amidoximes instead of amidines” strategy in the prodrug design have been summarized. The examples of prodrugs with a wide range of biological activities such as antiprotozoal and antithrombotic activity, as well as inhibitors of serine proteases of the sulfonamide type, antiviral prodrugs have been given. They are either introduced into production or are at the stage of clinical trials. In addition, the synthetic methods for amidoximes, and the synthesis of the known prodrugs have been also shown. The new approach to the drug modifi cation – the use of double prodrugs has been described. This strategy allows to obtain the derivatives with less basicity and improved lipophilicity,therefore, with better bioavailability. The synthesis of a single commercial oral thrombin inhibitor dabigatran etexilate (Pradaxa) as a dabigatran double prodrug, as well as amidine and amidoxime derivatives of the antiviral oseltamivir (Tamifl u) has been presented. 1,2,4-Oxadiazoles, masked amidoxime prodrugs have been used in the design of potential antimalarial, antifungal drugs and in order to obtain new oral GPIIb/IIIa antagonists.

Downloads

Download data is not yet available.

References

  1. Eloy F., Lenaers R. Chem. Rev., 1962, Vol. 62, pp.155-183.
  2. Nicolaides D. N., Varella E. A. In: Patai S., Ed., Interscience. The chemistry of acid derivatives; the chemistry of amidoximes. New York, 1992, Vol. 2 (Suppl. B, Pt 2), pp.875-966.
  3. Fylaktakidou K. C., Hadjipavlou-Litina D. J., Litinas K. E., Varella E. A., Nicolaides D. N. Curr. Pharm. Des., 2008, Vol. 14, pp.1001-1047.
  4. Peterlin-Mašič L., Kikelj D. Tetrahedron, 2001, Vol. 57, pp.7073-7105.
  5. Peterlin-Mašič L., Cesar J., Zega A. Curr. Pharm. Des., 2006, Vol. 12, pp.73-91.
  6. Fuller A. T. Biochem. J. 1947, Vol. 41, pp.403-408.
  7. Salom-Roig X. J., Hamzй A., Calas M., Vial H. J. Comb. Chem. High Throughput Screen., 2005, Vol. 8, pp.49-62.
  8. Werbovetz K. Curr. Opin. Investig. Drugs, 2006, Vol. 7, pp.147-157.
  9. Soeiro M. N. C., de Castro S. L., de Souza E. M., Batista D. G. J., Silva C. F., Boykin D. W. Curr. Mol. Pharmacol., 2008, Vol. 1, pp.151-161.
  10. Weller T., Alig L., Beresini M., Blackburn B., Bunting S., Hadvбry P., Mьller M. H., Knopp D., Levet-Tra™it B., Lipari M. T., Modi N. B., Mьller M., Re™ino C. J., Schmitt M., Schцnholzer P., Weiss S., Steiner B. J. Med. Chem., 1996, Vol. 39, pp.3139-3147.
  11. Clement B. Drug Metab. Rev., 2002, Vol. 34, pp.565-579.
  12. Bundgaard H. In Design of Prodrugs; Bundgaard, H., Ed.; Elsevier: Amsterdam, The Netherlands, 1985, p.1.
  13. Bundgaard H. In A Textbook of Drug Design and Development; Krogsgaard-Larsen P.; Bundgaard H., Eds.; Harwood Academic Publ.: Switzerland, 1991, p.113.
  14. Hu L. Drugs, 2004, Vol. 7, pp.736-742.
  15. Rautio J., Kumpulainen H., Heimbach T., Oliyai R., Oh D., Jдrvinen T., Savolainen J. Nat. Rev. Drug Discovery, 2008, Vol. 7, pp.255-268.
  16. Ott G., Havemeyer A., Clement B. J. Biol. Inorg. Chem., 2015, Vol. 20, pp.265-75.
  17. Jakobs H. H., Froriep D., Havemeyer A., Mendel R. R., Bittner F., Clement B. ChemMedChem, 2014, Vol. 9, pp.2381-2387.
  18. Clement B., Raether W. Arzneim.-Forsch., 1985, Vol. 35, pp.1009-1014.
  19. Clement B., Immel M., Terlinden R., Wingen F. J. Arch. Pharm., 1992, Vol. 325, pp.61-62.
  20. PCT Int. Appl. WO 2003017994 A1. Amidine derivatives for treating amyloidosis / R. J. Chalifour, X. Kong, X. Wu, W. Lu. Заявл.: 31.08.2001. Опубл.: 06.04.2003.
  21. Clement B., Bьrenheide A., Rieckert W., Schwarz J. Diacetyldiamidoximeester of pentamidine, a produg for treatment of protozoal diseases: synthesis, in vitro and in vivo biotransformation. ChemMedChem, 2006, Vol. 1, pp.1260-1267.
  22. Kotthaus J., Hungeling H., Reeh C., Kotthaus J., Schade D., Wein S., Wolffram S., Clement B. Bioorg. Med. Chem., 2011, Vol. 19, pp.1907-1914.
  23. Kotthaus J., Kotthaus J., Schade D., Schwering U., Hungeling H., Mueller-Fielitz H., Raasch W., Clement B. ChemMedChem, 2011, Vol. 6, pp.2233-2242.
  24. PCT Int. Appl. WO 2013014059 A1 20130131. Pentamidine amidoxime acid esters as prodrugs and use thereof as drugs / B. Clement, J. Kotthaus, J. Kotthaus, D. Schade. Заявл.: 25.07.2011. Опубл.: 31.01.2013.
  25. Hall J. E., Kerrigan J. E., Ramachandran K., Bender B. C., Stanko J. P., Jones S. K., Patrick D. A., Tidwell R. R. Antimicrob. Agents Chemother. 1998, Vol. 42, pp.666-674.
  26. Patrick D. A., Hall J. E., Bender B. C., McCurdy D. R., Wilson W. D., Tanious F. A., Saha S., Tidwell R. R. Eur. J. Med. Chem. 1999, Vol. 34, pp.575-583.
  27. Huang T. L., Bacchi C. J., Kode N. R., Zhang Q., Wang G., Yartlet N., Rattendi D., Londono I., Mazumder L., Vanden Eynde J. J., Mayence A., Donkor I. O. Int. J. Antimicrob. Agents, 2007, Vol. 30, pp.555-561.
  28. Branowska D., Farahat A. A., Kumar A., Wenzler T., Brun R., Liu Y., Wilson W. D., Boykin D. W. Bioorg. Med. Chem., 2010, Vol. 18, pp.3551-3558.
  29. Paine M. F., Wang M. Z., Generaux C. N., Boykin D. W., Wilson W. D., De Koning H. P., Olson C. A., Pohlig G., Burri C., Brun R., Murilla G. A., Thuita J. K., Barrett M. P., Tidwell R. R. Curr. Opin. Investig. Drugs, 2010, Vol. 11, pp.876-883.
  30. Bouhlel A., Curti C., Dumиtre A., Laget M., Crozet M. D., Azas N., Vanelle P. Bioorg. Med. Chem., 2010, Vol. 18, pp.7310-7320.
  31. Margout D., Gattacceca F., Moarbess G., Wein S., Tran van Ba C., Le Pape S., Berger O., Escale R., Vial H. J., Bressolle F. M. Eur. J. Pharm. Sci., 2011, Vol. 42, pp.81-90.
  32. PCT Int. Appl. WO 9723499 A1 19970703. Prodrugs of thrombin inhibitors / T. Antonsson, D. Gustafsson, K.-J. Hoffmann et al. Заявл.: 21.12.1995. Опубл.: 03.07.1997.
  33. Gustafsson D., Elg M. Thromb. Res., 2003, Vol. 109, pp.9-15.
  34. Clement B., Lopian K. Drug Metab. Dispos., 2003, Vol. 31, pp.645-651.
  35. Van Ryn J., Stangier J., Haertter S., Liesenfeld K.-H., Wienen W., Feuring M., Clemens A. Thromb. Haemost., 2010, Vol. 103, pp.1116-1127.
  36. Eur. Pat. Appl. EP 2550966 A1 20130130. Dabigatran-amidoxime acid esters as prodrugs and use thereof as pharmaceuticals / B. Clement, J. Kotthaus, J. Kotthaus, D. Schade. Заявл.: 25.07.2011. Опубл.: 30.01.2013.
  37. PCT Int. Appl. WO2013111163 A2 20130801. Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof / S. D. Dwivedi, R. C. Singh, J. M. Raval. Заявл.: 20.01.2012. Опубл.: 01.08.2013.
  38. PCT Int. Appl. WO 2013013946 A1 20130131. Dabigatran-amidoxime acid esters as prodrugs and use thereof as pharmaceuticals / B. Clement, J. Kotthaus, J. Kotthaus, D. Schade. Заявл.: 25.07.2011. Опубл.: 31.01.2013.
  39. Froriep D., Clement B., Bittner F., Mendel R. R., Reichmann D., Schmalix W., Havemeyer A. Xenobiotica, 2013, Vol. 43, pp.780-784.
  40. Meyer J. E., Brocks C., Graefe H., Mala C., Thдns N., Bьrgle M., Rempel A., Rotter N., Wollenberg B., Lang S. Breast Care, 2008, Vol. 3, pp.20-24.
  41. PCT Int. Appl. WO 2004103984 A1 20041202. Synthesis of hydroxyamidine and hydroxyguanidine amino acid or oligopeptide derivatives for use as urokinase plasminogen activator inhibitors for the treatment of cancer and its metastasis / S. Sperl, M. Burgle, W. Schmalix, K. Wosikowski, B. Clement. Заявл.: 26.05.2003. Опубл.: 02.12.2004.
  42. U.S. Pat. Appl. Publ. US 20060142305 A1 20060629. Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors / S. Sperl, M. Burgle, W. Schmalix, K. Wosikowski, B. Clement. Заявл.: 26.05.2003. Опубл.: 29.06.2006.
  43. Kotthaus J., Steinmetzer T., van de Locht A., Clement B. J. Enzym Inhib. Med. Chem., 2011, Vol. 26, pp.115-122.
  44. Uchida M., Okazaki K., Mukaiyama H., Isawa H., Kobayashi H., Shiohara H., Muranaka H., Kai Y., Kikuchi N., Takeuchi H., Yokoyama K., Tsuji E., Ozawa T., Hoyano Y., Koizumi T., Misawa K., Hara K., Nakano S., Murakami Y., Okuno H. Bioorg. Med. Chem. Lett., 2008, Vol. 18, pp.4682-4687.
  45. Kim C. U., Lew W., Williams M. A., Wu H., Zhang L., Chen X., Escarpe P. A., Mendel D. B., Laver W. G., Stevens R. C. J. Med. Chem., 1998, Vol. 41, pp.2451-2460
  46. Abrecht S., Federspiel M. C., Estermann H., Fischer R., Karpf M., Mair H.-J., Oberhauser T., Rimmler G., Trussardi R., Zutter U. Chimia, 2007, Vol. 61, pp.93-99.
  47. Karpf M., Trussardi R. J. Org. Chem., 2001, Vol. 66, pp.2044-2051.
  48. Federspiel M., Fischer R., Hennig M., Mair H.-J., Oberhauser T., Rimmler G., Albiez T., Bruhin J., Estermann H., Gandert C., Gockel V., Gotzo S., Hoffmann U., Huber G., Janatsch G., Lauper S., Rockel-Stabler O., Trussardi R., Zwahlen A. G. Org. Process Res. Dev., 1999, Vol. 3, pp.266-274.
  49. Rohloff J. C., Kent K. M., Postich M. J., Becker M. W., Chapman H. H., Kelly D. E., Lew W., Louie M. S., McGee L. R., Prisbe E. J., Schultze L. M., Yu R. H., Zhang L. J. Org. Chem., 1998, Vol. 63, pp.4545-4550.
  50. Schade D., Kotthaus J., Riebling L., Kotthaus J., Mueller-Fielitz H., Raasch W., Koch O., Seidel N., Schmidtke M., Clement B. J. Med. Chem., 2014, Vol. 57, pp.759-769.
  51. Bauch E., Reichmann D., Mendel R.-R., Bittner F., Manke A.-M., Kurz P., Girreser U., Havemeyer A., Clement B. ChemMedChem, 2015, Vol. 10, pp.360-367.
  52. Schwarz L., Girreser U., Clement B. Eur. J. Org. Chem., 2014, Vol. 9, pp.1961-1975.
  53. Ouattara M., Wein S., Calas M., Hoang Y. V., Vial H., Escale R. Bioorg. Med. Chem. Lett., 2007, Vol. 17, pp.593-596.
  54. Kode N. R., Vanden Eynde J. J., Mayence A., Wang G., Huang T. L. Molecules, 2013, Vol. 18, pp.11250-11263.
  55. Kitamura S., Fukushi I., Miyawaki T., Kawamura M., Terashita E., Naka T. Chem. Pharm. Bull., 2001, Vol.49, pp.268-277.

Downloads

Published

2016-03-04

How to Cite

(1)
Ovdiichuk, O. V.; Hordiyenko, O. V. Amidoximes and Their Masked Derivatives As Prodrugs of Amidines – Arginine Mimetics. J. Org. Pharm. Chem. 2016, 14, 36-45.

Issue

Vol. 14 No. 1(53) (2016)

Section

Original Researches

License

Copyright (c) 2016 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors publishing their works in the Journal of Organic and Pharmaceutical Chemistry agree with the following terms:

1. Authors retain copyright and grant the journal the right of the first publication of the work under Creative Commons Attribution License allowing everyone to distribute and re-use the published material if proper citation of the original publication is given.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book) providing proper citation of the original publication.

3. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on authors’ personal websites) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).